Claims for Patent: 7,687,610

Summary for Patent: 7,687,610

Title:	Human chorionic gonadotropin superagonists
Abstract:	The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the .alpha.-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the .beta.-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone. The invention is also directed to a method of constructing superactive nonchimeric analogs of human hormones comprising comparing the amino acid sequence of a more active homolog from another species to the human hormone, and selecting superactive analogs from the substituted human hormones. The invention is also directed to nucleic acids encoding the modified human glycoprotein hormones, vectors containing those nucleic acids, and host cells containing those vectors.
Inventor(s):	Szkudlinski; Mariusz W. (Potomac, MD), Weintraub; Bruce D. (Rockville, MD), Grossmann; Mathis (Parkville, AU)
Assignee:	The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:	11/409,428
Patent Claims:	1. A modified human chorionic gonadotropin (hCG) comprising an .alpha. subunit and a .beta. subunit, said .alpha. subunit comprising at least three basic amino acids at positions selected from the group consisting of positions 11, 13, 14,16, 17, and 20. 2. The modified hCG of claim 1, wherein said .alpha. subunit further comprises a fourth basic amino acid at a position selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. 3. The modified hCG of claim 2, wherein said basic amino acids in the .alpha. subunit are at positions 11, 13, 16, and 20. 4. The modified hCG of claim 2, wherein said basic amino acids in the .alpha. subunit are at positions 11, 13, 17, and 20. 5. The modified hCG of claim 2, wherein said basic amino acids in the .alpha. subunit are at positions 13, 14, 16, and 20. 6. The modified hCG of claim 2, wherein said basic amino acids in the .alpha. subunit are at positions 13, 14, 17, and 20. 7. The modified hCG of claim 2, said .alpha. subunit further comprising a fifth basic amino acid at a position selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. 8. The modified hCG of claim 7, wherein said basic amino acids in the .alpha. subunit are at positions 13, 14, 16, 17, and 20. 9. The modified hCG of claim 7, wherein said basic amino acids in the .alpha. subunit are at positions 11, 13, 14, 16 and 20. 10. The modified hCG of claim 1, wherein said basic amino acids in the .alpha. subunit are at positions 11, 13, 14, 16, 17, and 20. 11. The modified hCG of claim 1, wherein said basic amino acids in the .alpha. subunit are at positions 13, 16, and 20. 12. The modified hCG of claim 1, wherein the modified hCG comprises a basic amino acid in at least one position selected from the group consisting of positions in the .beta.-subunit of hCG, corresponding to positions 58 and 69 of the .beta.-subunit of the human thyroid stimulating hormone. 13. The modified hCG of claim 11, wherein the activity of the modified hCG is increased by at least 3 fold. 14. The modified hCG of claim 1, wherein the basic amino acids are lysine. 15. The modified hCG of claim 1, wherein the basic amino acids are selected from the group consisting of lysine and arginine. 16. A method of assisting reproduction in a subject comprising administering an assisting amount of the modified hCG of claim 1. 17. A nucleic acid encoding the modified hCG of claim 1. 18. A vector comprising the nucleic acid of claim 17, wherein the vector is suitable for expressing the nucleic acid. 19. A host comprising the vector of claim 18, wherein the host is suitable for expressing the nucleic acid. 20. The modified hCG of claim 1 further modified so that the modified hCG has less than five amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 21. The modified hCG of claim 1, wherein the modified hCG has less than four amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 22. The modified glycoprotein hormone of claim 1, wherein the modified hCG has less than three amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 23. The modified hCG of claim 1, wherein the modified hCG has less than two amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 24. The modified hCG of claim 1, wherein the modified hCG has complete amino acid sequence homology with hCG in positions other than positions 11, 13, 14, 16, 17, and 20 of the .alpha.-subunit. 25. A modified human chorionic gonadotropin (hCG) comprising a basic amino acid in the .alpha.-subunit in at least one position selected from the group consisting of positions 11, 13, 14, 16, 17 and 20. 26. The modified hCG of claim 25, wherein a basic amino acid is at position 11. 27. The modified hCG of claim 25, wherein a basic amino acid is at position 13. 28. The modified hCG of claim 25, wherein a basic amino acid is at position 14. 29. The modified hCG of claim 25, wherein a basic amino acid is at position 16. 30. The modified hCG of claim 25, wherein a basic amino acid is at position 17. 31. The modified hCG of claim 25, wherein a basic amino acid is at position 20. 32. The modified hCG of claim 25, wherein the basic amino acid is selected from the group consisting of lysine and arginine. 33. The modified hCG of claim 32, wherein the basic amino acids are at positions 16 and 20. 34. The modified hCG of claim 33, wherein the basic amino acids are at positions 16 and 13. 35. The modified hCG of claim 33, wherein the basic amino acids are at positions 20 and 13. 36. The modified hCG of claim 33, wherein the basic amino acid is selected from the group consisting of lysine and arginine. 37. The modified hCG of claim 33, comprising a basic amino acid in at least two positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. 38. The modified hCG of claim 25, wherein the modified hCG further comprises a basic amino acid in at least one position selected from the group consisting of positions in the .beta.-subunit of hCG corresponding to positions 58 and 69 of the .beta.-subunit of the human thyroid stimulating hormone. 39. The modified hCG of claim 38, wherein the modified hCG comprises basic amino acids at positions in the .beta. subunit of hCG corresponding to positions 58 and 69 of the .beta.-subunit of the human thyroid stimulating hormone. 40. The modified hCG of claim 38, wherein a basic amino acid is at a position in the .beta. subunit of hCG corresponding to position 58 of the .beta.-subunit of the human thyroid stimulating hormone. 41. The modified hCG of claim 38, wherein a basic amino acid is at a position in the .beta. subunit of hCG corresponding to position 69 of the .beta.-subunit of the human thyroid stimulating hormone. 42. The modified hCG of claim 25 further modified so that the modified hCG has less than five amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 43. The modified hCG of claim 25, wherein the modified hCG has less than four amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 44. The modified hCG of claim 25, wherein the modified hCG has less than three amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 45. The modified hCG of claim 25, wherein the modified hCG has less than two amino acid substitutions in the .alpha.-subunit in positions other than positions 11, 13, 14, 16, 17, and 20. 46. The modified hCG of claim 25, wherein the modified hCG has the complete amino acid sequence homology with the wild-type hCG in positions other than positions 11, 13, 14,16, 17, and 20 of the .alpha.-subunit. 47. The modified of claim 25, wherein the modified hCG comprises a basic amino acid in at least one position selected from the group consisting of positions in the .beta.-subunit of glycoprotein hormones other than the thyroid stimulating hormone, corresponding to positions 58 and 69 of the .beta.-subunit of the human thyroid stimulating hormone. 48. A nucleic acid encoding the modified hCG of claim 25. 49. A vector comprising the nucleic acid of claim 48, wherein the vector is suitable for expressing the nucleic acid. 50. A host comprising the vector of claim 49, wherein the host is suitable for expressing the nucleic acid.

Details for Patent 7,687,610

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	7,687,610	2026-04-21
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	7,687,610	2026-04-21
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	7,687,610	2026-04-21
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	7,687,610	2026-04-21
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	7,687,610	2026-04-21